[go: up one dir, main page]

WO2008140499A3 - Method for treating sepsis - Google Patents

Method for treating sepsis Download PDF

Info

Publication number
WO2008140499A3
WO2008140499A3 PCT/US2007/024588 US2007024588W WO2008140499A3 WO 2008140499 A3 WO2008140499 A3 WO 2008140499A3 US 2007024588 W US2007024588 W US 2007024588W WO 2008140499 A3 WO2008140499 A3 WO 2008140499A3
Authority
WO
WIPO (PCT)
Prior art keywords
sepsis
treating sepsis
condition
treating
induced condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/024588
Other languages
French (fr)
Other versions
WO2008140499A2 (en
Inventor
Debbie Quinn
Hari G Garg
Charles A Hales
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2008140499A2 publication Critical patent/WO2008140499A2/en
Publication of WO2008140499A3 publication Critical patent/WO2008140499A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method of treating and/or preventing sepsis or a sepsis-induced condition in a subject in need thereof or who is at risk of developing sepsis or a sepsis-induced condition, e.g. an inflammatory condition, by the systemic administration of high-molecular weight hyaluronan.
PCT/US2007/024588 2006-11-29 2007-11-28 Method for treating sepsis Ceased WO2008140499A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86146106P 2006-11-29 2006-11-29
US60/861,461 2006-11-29

Publications (2)

Publication Number Publication Date
WO2008140499A2 WO2008140499A2 (en) 2008-11-20
WO2008140499A3 true WO2008140499A3 (en) 2009-01-15

Family

ID=40002793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024588 Ceased WO2008140499A2 (en) 2006-11-29 2007-11-28 Method for treating sepsis

Country Status (1)

Country Link
WO (1) WO2008140499A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI383796B (en) * 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
CA2851513A1 (en) * 2011-10-11 2013-04-18 Drp Biomedical, Inc. Method for treating acute kidney injury
US12419903B1 (en) * 2020-04-03 2025-09-23 Embrient Inc. Compositions and methods of treatment for various conditions using high-molecular weight hyaluronic acid
WO2022236585A1 (en) * 2021-05-10 2022-11-17 傅毓秀 Use of hyaluronic acid in preparation of medication for treating pulmonary fibrosis
WO2022236599A1 (en) * 2021-05-10 2022-11-17 傅毓秀 Use of hyaluronic acid for preparing medicament for treating acute respiratory distress syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585361A (en) * 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
US20040087492A1 (en) * 2000-01-10 2004-05-06 Saul Yedgar Use of lipid conjugates in the treatment of diseases
US20050058646A1 (en) * 1999-04-01 2005-03-17 Turley Eva A. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyalurons
US20060029662A1 (en) * 1999-04-06 2006-02-09 Genzyme Corporation Immunomodulatory compositions and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585361A (en) * 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
US20050058646A1 (en) * 1999-04-01 2005-03-17 Turley Eva A. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyalurons
US20060029662A1 (en) * 1999-04-06 2006-02-09 Genzyme Corporation Immunomodulatory compositions and methods of use thereof
US20040087492A1 (en) * 2000-01-10 2004-05-06 Saul Yedgar Use of lipid conjugates in the treatment of diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASCARENHAS M.M. ET AL.: "Low Molecular Weight hyaluronan from Stretched Lung Enhances Interleukin-8 Expression", AM. J. RESPIR. CELL MOL. BIOL., vol. 30, 2004, pages 52 *
NAKAMURA K. ET AL.: "High, but not low, molecular weight hyaluronan prevents T-cell mediated liver injury by reducing proinflammatory cytokines in mice", J. OF GASTROENTEROLOGY, vol. 39, 2004, pages 346 - 347, 350 - 351 *

Also Published As

Publication number Publication date
WO2008140499A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008057246A3 (en) Method for treating inflammatory disorders
WO2008030427A3 (en) Passive in vivo substance spectroscopy
WO2009043051A3 (en) Cd23 binding molecules and methods of use thereof
WO2009109908A8 (en) Methods of treating inflammatory pain
WO2008066642A3 (en) Transdermal delivery systems comprising bupivacaine
BRPI0916576A2 (en) at least one chemical entity, pharmaceutical composition, and method for treating a condition or disorder.
ATE483388T1 (en) SUPPORT ARRANGEMENT
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2007150015A3 (en) Method of treatment
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2008005375A3 (en) Kidney toxicity biomarkers
WO2007044763A3 (en) System and method for detecting fraudulent transactions
BRPI0819842A2 (en) Charging system and method for operating the same.
WO2008060767A3 (en) Macrocyclic benzofused pyrimidine derivatives
WO2007131078A3 (en) Inflammatory condition progression, diagnosis and treatment monitoring methods, systems, apparatus, and uses
WO2008048991A3 (en) Organic compounds
WO2008046104A3 (en) Methods and systems for knowledge discovery
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2007038551A3 (en) Use of ibudilast for treating drug and behavioral addictions
WO2009100342A3 (en) Disease markers and uses thereof
BRPI0909201A2 (en) Pressure balancing device and process in at least one turborreator, and turborreator bearing housing.
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007126548A3 (en) Adaptive mission profiling
WO2010017443A3 (en) Anti-beta-2-microglobulin agents and the use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874155

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874155

Country of ref document: EP

Kind code of ref document: A2